Page 106 - Demo

104 Notes to the Consolidated Financial Statements During 2023, the Group has settled contingent considerations relating to the acquisitions of Bosung for an amount of CHF 3.8 million (thereof fair value adjustments of CHF 0.8 million recorded under net cash flows from operating activities), Refarmed for an amount of CHF 6.3 million, DNIV for an amount of CHF 8.4 m and Acutest for an amount of CHF 0.4 m. The Group recorded net income from revaluation of contingent consideration liabilities of CHF 1.0 million in the finance result.During 2023 the Group has received reimbursements of purchase consideration for Terra Firma and Georg Breuer based on final closing adjustments for an amount of CHF 1.3 million.DisposalsDuring the business year 2023, the Group has disposed its interest in DKSH Smollan Fieldmarketing businesses in Malaysia, Thailand, Taiwan and Vietnam to the minority shareholder partner Smollan. Upon disposal, the Group has derecognized principally net working capital of CHF 9.2 million (including cash and cash equivalents of CHF 4.9 million), goodwill of CHF 1.1 million and non-controlling interest of CHF 3.9 million. Based on a sales price of CHF 4.2 million the Group has recorded a loss on sale of business of CHF 2.0 million (including recycling of currency translation adjustments of CHF 0.9 million). Prior Year AcquisitionsDuring the business year 2022, the Group acquired the following businesses:Effective October 31, 2022, the Group purchased 82.4% of the interests in Terra Firma Group, a privately held business, based in US and Canada. The Terra Firma business represents a distributor of specialty chemicals in North America.The Group entered into the agreement to purchase the business based on an enterprise value formula on a cash and debt free basis. As part of the purchase agreement the Group paid CHF 79.5 million to settle third party debt of the Terra Firma entities and incentive payments on behalf of the sellers at closing. As part of the purchase of the interests the Group has entered into a put call option agreement to ac,quire the non-controlling interest to be exercised earliest ending 2025. The Group has concluded that it does not have a present ownership interest and therefore has recognised non-controlling interests measured at their proportionate share of net assets.Effective July 1, 2022, the Group purchased the shares of Refarmed Group. The Refarmed business, based in Switzerland provides Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) for international generic drug manufacturers. This includes the sourcing of the ingredients as well as providing technical and regulatory support. Purchase consideration for Refarmed Group of CHF 63.4 million was paid in cash in 2022. Contingent consideration liabilities with a fair value of CHF 19.1 million were recognized at the acquisition date. Payments are contingent on the achievement of normalized EBITDA targets of the acquired business for the financial years ending 2022, 2023 and 2024 and include a target floor of 80.0%Effective July 1, 2022, the Group purchased the shares of DNIV Group headquartered in Singapore. The DNIV business, active in Singapore, Malaysia, Thailand and China provides high-tech manufacturing solutions for the semiconductor and electronics industry. The business includes engineering expertise covering the entire life cycle from installation to commissioning, training, application support, repair and maintenance, and spare parts.